Durata Therapeutics to Present Five Posters at IDWeek 2014
October 2, 2014Durata Therapeutics announced that it will present five posters highlighting data from its recently launched product, DALVANCE™ at IDWeek 2014, October 8-11 in Philadelphia.
More »
Esperion Therapeutics Announces Positive Top-Line Phase 2b Results for ETC-1002, An Investigational Therapy for Patients with Hypercholesterolemia
October 1, 2014Esperion Therapeutics announced positive top-line Phase 2b results for ETC-1002 monotherapy compared with ezetimibe monotherapy in patients with hypercholesterolemia.
More »
Zogenix Submits Modified Formulation of Zohydro(R) ER With Potential Abuse Deterrent Properties for FDA Review
October 1, 2014Zogenix, Inc. announced it has submitted to the U.S. FDA a supplemental New Drug Application (sDNA) for a modified formulation of Zohydro ER. The Company anticipates a target action date on the drug Q1 of 2015.
More »